CombinatoRx to Present Data for Oncology Programs at American
Association for Cancer Research Meeting
Novel Synergistic Mechanisms Discovered for the Treatment of MultipleMyeloma Using CombinatoRx cHTS Technology
CAMBRIDGE, Mass., Apr 15, 2010 (BUSINESS WIRE) --CombinatoRx, Incorporated (NASDAQ: CRXX) today announced that
preclinical data on its discovery of novel synergistic drug combinations
for the treatment of cancer will be highlighted at the 101st
Annual meeting of the American Association for Cancer Research 2010,
April 17-21, in Washington, DC. These preclinical studies reinforce the
rationale for investigation of A2A and B2AR agonists in the treatment of
multiple myeloma and other B-cell malignancies and highlight the power
of the CombinatoRx combination high throughput screening (cHTS(TM))
technology to interrogate combination activity across large panels of
cancer cells to identify novel mechanisms for therapeutic application.
Abstract #5509: Wednesday, April 21, 2010, 8:00 AM - 11:00 AM,
"Identification of synergistic drugs using combination high-throughput
screening," Rickles, et.al., Exhibit Hall A-C, Poster Section 25, ,
Poster Board 29.
CombinatoRx, Incorporated (CRXX) develops novel drug candidates with a
focus on the treatment of pain and inflammation. The company applies its
combination drug discovery capabilities and its selective ion-channel
modulation platform to generate innovative therapeutics. To learn more
about CombinatoRx, please visit www.combinatorx.com.
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995
concerning CombinatoRx, the CombinatoRx cHTS drug discovery technology,
and the business plans of CombinatoRx. These forward-looking statements
about future expectations, plans, objectives and prospects of
CombinatoRx may be identified by words like "believe," "expect," "may,"
"will," "should," "seek," or "could" and similar expressions and involve
significant risks, uncertainties and assumptions, including risks
related to the unproven nature of the CombinatoRx cHTS drug discovery
technology, the Company's ability to obtain additional financing or
funding for its research and development and those other risks that can
be found in the "Risk Factors" section of the Company's annual report on
Form 10-K on file with the Securities and Exchange Commission and the
other reports that CombinatoRx periodically files with the Securities
and Exchange Commission. Actual results may differ materially from those
CombinatoRx contemplated by these forward-looking statements. These
forward looking statements reflect management's current views and
CombinatoRx does not undertake to update any of these forward-looking
statements to reflect a change in its views or events or circumstances
that occur after the date of this release except as required by law.
(c) 2010 CombinatoRx, Incorporated. All rights reserved.